{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-081797","form_type":"8-K","ticker":"ONCY","cik":"0001129928","company_name":"ONCOLYTICS BIOTECH INC","filed_at":"2026-07-08T20:23:21+00:00","discovered_at":"2026-07-08T20:24:00.522311+00:00","generated_at":"2026-07-08T20:24:06.032931+00:00","sec_items":["4.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Oncolytics Biotech disengages EY, engages Baker Tilly as auditor after restructuring","bullets":["Audit committee voted to disengage EY and engage Baker Tilly for fiscal 2026, subject to client acceptance.","EY's reports for 2024 and 2025 contained no adverse opinion but included a going-concern explanatory paragraph.","No disagreements or reportable events with EY during the fiscal years ended 2024 and 2025.","Company provided EY with a copy of the 8-K and requested a letter to the SEC regarding the statements."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-081797","json":"https://secwatch.observer/filing/0001104659-26-081797.json","markdown":"https://secwatch.observer/filing/0001104659-26-081797.md","text":"https://secwatch.observer/filing/0001104659-26-081797.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1129928/000110465926081797/0001104659-26-081797-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1129928/000110465926081797/tm2620055d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-08T20:24:06.032931+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}